PGJ2-stimulated beta-cell apoptosis is associated with prolonged UPR activation.
Peroxisome proliferator-activated receptor-gamma (PPARgamma) ligands have been shown to possess anti-inflammatory properties that include the inhibition of transcription factor activation and the expression of inflammatory genes. Using pancreatic beta-cells, we have shown that PPARgamma ligands such as 15-deoxy-Delta(12,14)-prostaglandin J(2) (PGJ(2)) attenuate interferon-gamma-induced signal transducer and activator of transcription 1 activation and interleukin (IL)-1beta-induced nuclear factor-kappaB activation by a pathway that correlates with endoplasmic reticulum stress and the induction of the unfolded protein response (UPR). The UPR is a conserved cellular response activated by a number of cell stressors and is believed to alleviate the stress and promote cell survival. However, prolonged activation of the UPR results in cellular death by apoptosis. In this report, we have examined the effects of PGJ(2) on UPR activation and the consequences of this activation on cell survival. Consistent with induction of a cell death pathway, treatment of rat islets and RINm5F cells for 24 h with PGJ(2) results in caspase-3 activation and caspase-dependent beta-cell death. The actions of these ligands do not appear to be selective for beta-cells, because PGJ(2) stimulates macrophage apoptosis in a similar fashion. Associated with cell death is the enhanced phosphorylation of eukaryotic initiation factor 2alpha (eIF2alpha), and in cells expressing a mutant of eIF2alpha that cannot be phosphorylated, the stimulatory actions of PGJ(2) on caspase-3 activation are augmented. These findings suggest that, whereas PGJ(2)-induced UPR activation is associated with an inhibition of cytokine signaling, prolonged UPR activation results in cell death, and that eIF2alpha phosphorylation may function in a protective manner to attenuate cell death.
Chambers
Kari T
KT
Saint Louis University School of Medicine, Edward A. Doisy Department of Biochemistry and Molecular Biology, 1402 South Grand Blvd., St. Louis, MO 63104, USA.
Weber
Sarah M
SM
Corbett
John A
JA
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D053148:Caspase 3 / Q000378:metabolism / Q000502:physiology; D002478:Cells, Cultured; D004789:Enzyme Activation / Q000187:drug effects; D015852:Eukaryotic Initiation Factor-2 / Q000235:genetics / Q000378:metabolism; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D007340:Insulinoma / Q000473:pathology / Q000503:physiopathology; D008024:Ligands; D008264:Macrophages / Q000187:drug effects / Q000502:physiology; D008297:Male; D051379:Mice; D009154:Mutation; D047495:PPAR gamma / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000503:physiopathology; D010766:Phosphorylation; D015230:Prostaglandin D2 / Q000031:analogs & derivatives* / Q000494:pharmacology; D017510:Protein Folding; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D015852:Eukaryotic Initiation Factor-2; D008024:Ligands; D047495:PPAR gamma; C037112:9-deoxy-delta-9-prostaglandin D2; D053148:Caspase 3; D015230:Prostaglandin D2